Literature DB >> 19525353

Presynaptic regulation of dopamine transmission in schizophrenia.

Gholson J Lyon1, Anissa Abi-Dargham, Holly Moore, Jeffrey A Lieberman, Jonathan A Javitch, David Sulzer.   

Abstract

A role for dopamine (DA) release in the hallucinations and other positive symptoms associated with schizophrenia has long been inferred from the antipsychotic response to D2 DA receptor antagonists and because the DA releaser amphetamine can be psychotogenic. Recent studies suggest that patients with schizophrenia, including those never exposed to antipsychotic drugs, maintain high presynaptic DA accumulation in the striatum. New laboratory approaches are elucidating mechanisms that control the level of presynaptic DA stores, thus contributing to fundamental understanding of the basic pathophysiologic mechanism in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525353      PMCID: PMC3004182          DOI: 10.1093/schbul/sbp010

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  121 in total

1.  3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors:  A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal:  Nature       Date:  1957-11-30       Impact factor: 49.962

2.  Neonatal ventral hippocampal lesions potentiate amphetamine-induced increments in dopamine efflux in the core, but not the shell, of the nucleus accumbens.

Authors:  Maria G Corda; Giovanna Piras; Osvaldo Giorgi
Journal:  Biol Psychiatry       Date:  2006-08-24       Impact factor: 13.382

Review 3.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

4.  Early detection of schizophrenia: current evidence and future perspectives.

Authors:  Heinz Häfner; Kurt Maurer
Journal:  World Psychiatry       Date:  2006-10       Impact factor: 49.548

5.  Prefrontal cortical projections to the midbrain in primates: evidence for a sparse connection.

Authors:  William Gordon Frankle; Mark Laruelle; Suzanne N Haber
Journal:  Neuropsychopharmacology       Date:  2006-01-04       Impact factor: 7.853

6.  Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.

Authors:  J Lavalaye; D H Linszen; J Booij; P M Dingemans; L Reneman; J B Habraken; B P Gersons; E A van Royen
Journal:  Schizophr Res       Date:  2001-01-15       Impact factor: 4.939

Review 7.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

8.  Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning.

Authors:  Christoph Kellendonk; Eleanor H Simpson; H Jonathan Polan; Gaël Malleret; Svetlana Vronskaya; Vanessa Winiger; Holly Moore; Eric R Kandel
Journal:  Neuron       Date:  2006-02-16       Impact factor: 17.173

9.  Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1.

Authors:  Mei-Chun Hsiao; Kun-Ju Lin; Chia-Yih Liu; Kai-Yuan Tzen; Tzu-Chen Yen
Journal:  Schizophr Res       Date:  2003-12-01       Impact factor: 4.939

10.  Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance?

Authors:  Arturas Petronis; Irving I Gottesman; Peixiang Kan; James L Kennedy; Vincenzo S Basile; Andrew D Paterson; Violeta Popendikyte
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

View more
  26 in total

1.  Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

2.  Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

3.  Dopamine transporter endocytic trafficking in striatal dopaminergic neurons: differential dependence on dynamin and the actin cytoskeleton.

Authors:  Luke R Gabriel; Sijia Wu; Patrick Kearney; Karl D Bellvé; Clive Standley; Kevin E Fogarty; Haley E Melikian
Journal:  J Neurosci       Date:  2013-11-06       Impact factor: 6.167

Review 4.  Sleep disturbance as transdiagnostic: consideration of neurobiological mechanisms.

Authors:  Allison G Harvey; Greg Murray; Rebecca A Chandler; Adriane Soehner
Journal:  Clin Psychol Rev       Date:  2010-04-24

5.  Presynaptic and extrasynaptic regulation of posterior nucleus of thalamus.

Authors:  Anthony Park; Ying Li; Radi Masri; Asaf Keller
Journal:  J Neurophysiol       Date:  2017-03-22       Impact factor: 2.714

Review 6.  Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia.

Authors:  Nao Chuhma; Susana Mingote; Abigail Kalmbach; Leora Yetnikoff; Stephen Rayport
Journal:  Biol Psychiatry       Date:  2016-07-12       Impact factor: 13.382

7.  Physiological and behavioral effects of amphetamine in BACE1(-/-) mice.

Authors:  R Madelaine Paredes; E Piccart; E Navaira; D Cruz; M A Javors; W Koek; M J Beckstead; C Walss-Bass
Journal:  Genes Brain Behav       Date:  2015-05-21       Impact factor: 3.449

8.  Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.

Authors:  Jee In Kang; Hae-Jeong Park; Se Joo Kim; Kyung Ran Kim; Su Young Lee; Eun Lee; Suk Kyoon An; Jun Soo Kwon; Jong Doo Lee
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

Review 9.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

Review 10.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.